StockData
Evaxion A/S logo

Evaxion A/S (EVAX) stock

EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30
$2.54−0.24 (-8.63%)

Close on Nov 18, 2026Market cap $21.18MP/E –Yield –

Evaxion A/S revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2025 it was $7.53M, up 125.1% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.53M+125.1%
FY2024Dec 31, 2024$3.34M+4480.8%
FY2023Dec 31, 2023$73.00K–
FY2022Dec 31, 2022$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0–
Q2 FY2025Jun 30, 2025$37.00K–
Q2 FY2024Jun 30, 2024$154.00K–
Q2 FY2023Jun 30, 2023$0–

More Evaxion A/S figures

See a number that looks wrong?